BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 16784014)

  • 1. Significant improvement of specific bronchial hyperreactivity in asthmatic children after 4 months of treatment with a modified extract of dermatophagoides pteronyssinus.
    Ibero M; Castillo MJ
    J Investig Allergol Clin Immunol; 2006; 16(3):194-202. PubMed ID: 16784014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significant improvement in symptoms, skin test, and specific bronchial reactivity after 6 months of treatment with a depigmented, polymerized extract of Dermatophagoides pteronyssinus and D. farinae.
    Ferrer A; García-Sellés J
    J Investig Allergol Clin Immunol; 2003; 13(4):244-51. PubMed ID: 14989113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful management of mite-allergic asthma with modified extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae in a double-blind, placebo-controlled study.
    García-Robaina JC; Sánchez I; de la Torre F; Fernández-Caldas E; Casanovas M
    J Allergy Clin Immunol; 2006 Nov; 118(5):1026-32. PubMed ID: 17088125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific allergen immunotherapy: effect on immunologic markers and clinical parameters in asthmatic children.
    Cevit O; Kendirli SG; Yilmaz M; Altintas DU; Karakoc GB
    J Investig Allergol Clin Immunol; 2007; 17(5):286-91. PubMed ID: 17982919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-blind and placebo-controlled study to assess efficacy and safety of a modified allergen extract of Dermatophagoides pteronyssinus in allergic asthma.
    Ameal A; Vega-Chicote JM; Fernández S; Miranda A; Carmona MJ; Rondón MC; Reina E; García-González JJ
    Allergy; 2005 Sep; 60(9):1178-83. PubMed ID: 16076305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy with a depigmented, polymerized vaccine of Olea europaea pollen allergens. Significantly reduces specific bronchial and skin test reactivity in sensitized patients after one year of treatment.
    Guerra F; Daza JC; Almeda E
    J Investig Allergol Clin Immunol; 2003; 13(2):108-17. PubMed ID: 12968395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison between the use of adsorbed and aqueous immunotherapy material in Dermatophagoides pteronyssinus sensitive asthmatic children.
    Altintaş D; Akmanlar N; Güneşer S; Burgut R; Yilmaz M; Buğdayci R; Aksungur P
    Allergol Immunopathol (Madr); 1999; 27(6):309-17. PubMed ID: 10611556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of 1-year specific immunotherapy with standardized house dust mite vaccine on mild to moderate allergic asthmatic patients].
    Wang HY; Lin XP; Hao CL; Zhang CQ; Sun BQ; Zheng JP; Chen P; Sheng JY; Wu A; Zhong NS
    Zhonghua Jie He He Hu Xi Za Zhi; 2006 Oct; 29(10):679-87. PubMed ID: 17129496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in inflammatory and clinical parameters and in bronchial hyperreactivity asthmatic children sensitized to house dust mites following sublingual immunotherapy.
    Silvestri M; Spallarossa D; Battistini E; Sabatini F; Pecora S; Parmiani S; Rossi GA
    J Investig Allergol Clin Immunol; 2002; 12(1):52-9. PubMed ID: 12109533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and immunologic effects of sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, randomized, placebo-controlled study.
    Lue KH; Lin YH; Sun HL; Lu KH; Hsieh JC; Chou MC
    Pediatr Allergy Immunol; 2006 Sep; 17(6):408-15. PubMed ID: 16925685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunologic alterations and efficacy of subcutaneous immunotherapy with Dermatophagoides pteronyssinus in monosensitized and polysensitized patients.
    Soyyigit S; Guloglu D; Ikinciogullari A; Secil D; Oztuna D; Mungan D; Misirligil Z; Sin BA
    Ann Allergy Asthma Immunol; 2016 Mar; 116(3):244-251.e2. PubMed ID: 26945497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significant reduction of nonspecific bronchial reactivity in patients with Dermatophagoides pteronyssinus-sensitive allergic asthma under therapy with allergen-antibody complexes.
    Machiels JJ; Lebrun PM; Jacquemin MG; Saint-Remy JM
    Am Rev Respir Dis; 1993 Jun; 147(6 Pt 1):1407-12. PubMed ID: 8503552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Depigmented and polymerised house dust mite allergoid: allergen content, induction of IgG4 and clinical response.
    Gallego MT; Iraola V; Himly M; Robinson DS; Badiola C; García-Robaina JC; Briza P; Carnés J
    Int Arch Allergy Immunol; 2010; 153(1):61-9. PubMed ID: 20357486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of sublingual immunotherapy with high-dose mite extracts in asthma: a multi-center, double-blind, randomized, and placebo-controlled study in Taiwan.
    Niu CK; Chen WY; Huang JL; Lue KH; Wang JY
    Respir Med; 2006 Aug; 100(8):1374-83. PubMed ID: 16403616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of house dust mite specific immunotherapy on cysteinyl leukotriene production by blood leukocytes in subjects with perennial allergic rhinitis and asthma.
    Saraçlar Y; Sekerel BE; Kalayci O; Adalioğlu G; Tuncer A
    J Investig Allergol Clin Immunol; 1998; 8(2):98-104. PubMed ID: 9615303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefits of immunotherapy with a standardized Dermatophagoides pteronyssinus extract in asthmatic children: a three-year prospective study.
    Pifferi M; Baldini G; Marrazzini G; Baldini M; Ragazzo V; Pietrobelli A; Boner AL
    Allergy; 2002 Sep; 57(9):785-90. PubMed ID: 12169173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the long-term efficacy of 3- and 5-year house dust mite allergen immunotherapy.
    Stelmach I; Sobocińska A; Majak P; Smejda K; Jerzyńska J; Stelmach W
    Ann Allergy Asthma Immunol; 2012 Oct; 109(4):274-8. PubMed ID: 23010234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative study of tolerance between unmodified and high doses of chemically modified allergen vaccines of Dermatophagoides pteronyssinus.
    Casanovas M; Fernández-Caldas E; Alamar R; Basomba A
    Int Arch Allergy Immunol; 2005 Jul; 137(3):211-8. PubMed ID: 15956789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of one-year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma: a randomized, placebo-controlled, double-blind, double-dummy study.
    Yukselen A; Kendirli SG; Yilmaz M; Altintas DU; Karakoc GB
    Int Arch Allergy Immunol; 2012; 157(3):288-98. PubMed ID: 22041501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial.
    Eifan AO; Akkoc T; Yildiz A; Keles S; Ozdemir C; Bahceciler NN; Barlan IB
    Clin Exp Allergy; 2010 Jun; 40(6):922-32. PubMed ID: 20100188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.